Contact Us >
中文
Address:
5th Floor, Building 3, No.115 Xin Jun Huan Road, Minhang District, Shanghai, China
Information Building 2, NO.3576 Zhaolou Road, Pujiang Town,Minhang District, Shanghai, China
Customer Service Number:
+86 400-821-9890
(9:00 - 18:00, Monday - Friday )
Customer Service Email:
liul@origimed.com
About Us
OrigiMed CO., LTD.
is a tumor precision medicine company based on leading sequencing technology and driven by real-world big data. It is committed to providing precision medical services for cancer patients around the world.
NTRK Clinic
is the pan-cancer specialty clinic under OrigiMed for NTRK gene fusion. It has passed the EU CE-certified NTRK1/2/3 Gene Variation Detection Kit (Certificate No.: CIBG-20222116) to serve all solid tumors for adults and childrens, every adult and child with NTRK gene fusion cancer will benefit from more survival. At present, we have provided over 500 NTRK-positive cancer patients with full-course management services of accurate detection, treatment and follow-up.
NTRK1/2/3 Gene Variation Detection Kit
OrigiMed's NTRK1/2/3 Gene Variation Detection Kit and Software have completed EU CE certification, and obtained the registration license for in vitro diagnostic reagents issued by Centraal Informatiepunt Beroepen Gezondheidszorg (CIBG) (Certificate No.: CIBG- 20222116/ CIBG-20221712 ). This kit is used for qualitative detection of NTRK (Neuro Trophin Receptor Kinase) gene fusion information in neutral formalin-fixed paraffin-embedded (FFPE) solid tumor samples. For clinical reference only.
Clinical Network
In China, we have two online hospitals specializing in oncology,
cooperate with more than 500 large tertiary
hospitals and more than 3000 top doctors, and
serve more than 100,000 tumor patients, including
more than 500 NTRK-positive patients.
Medical Test
In China, we have CAP and
CLIA double-C certified laboratories, and several
third-party medical testing laboratories. The test reports are
internationally recognized,
which ensures the safe use of NTRK positive patients.
Pharmaceutical Companies Cooperation
As a trusted partner of biopharmaceutical companies, we have
reached strategic cooperation with many large pharmaceutical
companies such as Bayer, Takeda, Johnson & Johnson and Merck.
Among them,
the first pan-solid tumor NTRK1/2/3 detection kit developed in
cooperation with Bayer has been approved by EU CE
certification.
Business Insurance
As a leader in the insurance field in the industry, we have
established cooperative relationships with government insurance
programs in more than 40 cities in China, so that
more cancer patients can benefit from the treatment of millions of
NTRK drugs and get more survival benefits.
Clinical Data
We have multi-dimensional, wide coverage, high-quality real-world
tumor data. Covering the data of tens of thousands of Chinese
tumor patients, more than 600 tumor subtypes,
covering 34 provinces and cities, among which the
NTRK follow-up data exceeds 500 cases.
One-Stop Solution
for Pharmaceutical Partners
for Pharmaceutical Partners
OrigiMed has partnered with multiple established pharma companies to provide One-Stop Solutions for key differences in cancer treatment, including companion diagnostics and real world insights services.
NTRK Clinic
NTRK Fusions
NTRK gene fusions can lead to the transformation of normal cells into cancer cells, and it can occur in many types of tumors, but is more common in rare tumors.
NTRK Detections
Now, DNA+RNA-based NGS detection is clinically recommended to detect NTRK fusions more comprehensively, avoiding missed and false detections to the greatest extent possible.
NTRK Drugs
Until now, NTRK drugs that have been marketed around the world include larotrectinib and entrectinib, opening a new era of targeted drug therapy for pan-solid tumors.
The Experts Message
Patient Benefit
Larotrectinib benefits
pediatric patients
Xiaoxinyue
pediatric patients
Xiaoxinyue
My mother often said that I was the lucky one who was blessed
by fate, and after taking this medicine (larotrectinib), I no
longer suffered from the pain.
Larotrectinib benefits
adult patients
Keith
adult patients
Keith
As long as your doctor and you know enough about tumors, there
are more chances to find the right treatment!
Jason
benefited from
entrectinib
benefited from
entrectinib
The life of a cancer patient is like running a marathon. You
need to have a strong will and the belief not to give up.
After three years of entrectinib treatment, I am now back to a
normal life.
Linda
benefited from
entrectinib
benefited from
entrectinib
I am a patient with an NTRK gene fusion mutation, and my
doctor told me that this is another door that God has opened
for me.
Tel：+86
400-821-9890
E-mail：liul@origimed.com
Website：www.origimed.com//en_home.html
